LPS-induced chronic Parkinson's disease in mice α-synuclein in the emergence and metastasis

Abstract

Abstract:

AIM: To establish a mouse model of chronic Parkinson's disease(PD) induced by lipopolysaccharide (LPS) and to investigate the behavioral changes of PD mice and the appearance and metastasis of α-synuclein(α-Syn) aggregates in the intestinal wall. METHODS: 48 male C57BL/6J mice were randomly divided into normal saline control group and PD model group at 6 weeks of age. The PD mice model was established by intraperitoneal injection of LPS. Behavioral changes of the experimental mice were detected by the rotating bar test and field test. The dopaminergic neuron loss and α-Syn were observed by immunohistochemistry nuclear protein expression and metastasis. RESULTS:Behavioral changes of PD model mice exhibited significance difference (P<0.01). PD model mice's substantia nigra pars compacta α-Syn aggregation first appeared in the gut, and over time, the α-Syn was transferred to the substantia nigra of the mesencephalon, and the dopaminergic neurons were severely damaged. CONCLUSION: In the LPS-induced PD model, the typical pathological changes (α-Syn aggregation) begin in the colon nerves, and gradually develop into the substantia nigra pars compacta, resulting in dopaminergic neuron damage and loss.

Key words: lipopolysaccharide, Parkinson's disease, α-synuclein, dopaminergic neurons

CLC Number:

R965.2

GE Bobo，QU Hongdang，CHEN Yuhua，HU Caicai，LI Li，JIANG Mujun，XU Juanjuan. LPS-induced chronic Parkinson's disease in mice α-synuclein in the emergence and metastasis[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2017, 22(3): 241-248.

References

［1］Goetz CG. The history of Parkinson's disease: early clinical descriptions and neurological therapies［J］. Cold Spring Harb Perspect Med, 2011, 1(1): a008862.
［2］Dickson DW, Braak H, Duda JE, et al. Neuropathological assessment of Parkinson's disease: refining the diagnostic criteria［J］.Lancet Neurol, 2009,8: 1150-1157.
［3］屈洪党, 史肖锦. 内质网应激介导的白藜芦醇对MPTP 诱导的小鼠帕金森病模型的神经保护作用［J］. 中国临床药理学与治疗学, 2016,21(1) : 28-32.
［4］Beach TG, Corbillé AG, Letournel F, et al. Multicenter assessment of immunohistochemical methods for pathological alpha-synuclein in sigmoid colon of autopsied Parkinson's disease and control subjects［J］. J Parkinsons Dis, 2016, 6(4):761-770.
［5］Marras C, Lang A. Parkinson's disease subtypes: lost in translation［J］? J Neurol Neurosurg Psychiatry, 2013, 84: 409-415.
［6］Luk KC, Kehm VM, Zhang B, et al. Intracerebral inoculation of pathological a-synuclein initiates a rapidly progressive neurodegenerative a-synucleinopathy in mice［J］. J Exp Med, 2012,209(5):975-986.
［7］Del TK, Hawkes CH, Ghebremedhin E, et al. Lewy pathology in the submandibular gland of individuals with incidental Lewy body disease and sporadic Parkinson's disease［J］. Acta Neuropathol, 2010,119（6）:703-713.
［8］Beach TG, Adler CH, Sue LI, et al. Multi-organ distribution of phosphorylated alpha-synuclein histopathology in subjects with Lewy body disorders［J］. Acta Neuropathol, 2010, 119（6）:689-702.
［9］Iwanaga K, Wakabayashi K, Yoshimoto M, et al. Lewy body-type degeneration in cardiac plexus in Parkinson's and incidental Lewy body diseases［J］. Neurology, 1999, 52（6）: 1269-1271.
［10］Fumimura Y, Ikemura M, Saito Y, et al. Analysis of the adrenal gland is useful for evaluating pathology of the peripheral autonomic nervous system in lewy body disease［J］. J Neuropathol Exp Neurol, 2007, 66(5): 354-362.
［11］Lebouvier T,Neunlist M,Bruley des VS,et al.Colonic biopsies to assess the neuropathology of Parkinson's disease and its relationship with symptoms［J］. PLoS One,2011,5（9）:e12728.
［12］Shannon KM, Keshavarzian A, Mutlu E, et al. Alpha-synuclein in colonic submucosa in early untreated Parkinson's disease［J］.Mov Disord, 2012,27(6): 709-715.
［13］Ling Z, Gayle DA, Ma SY, et al. In utero bacterial endotoxin exposure causes loss of tyrosine hydroxylase neurons in the postnatal rat midbrain［J］. Mov Disord, 2002, 17(1): 116-124.
［14］Gao HM, Jiang J, Wilson B, et al. Microglial activation-mediated delayed and progressive degeneration of rat nigral dopaminergic neurons: relevance to Parkinson's disease［J］. J Neurochem, 2002, 81(6): 1285-1297.
［15］Beach TG, Adler CH, Sue LI, et al. Multi-organ distribution of phosphorylated alpha-synuclein histopathology in subjects with Lewy body disorders［J］. Acta Neuropathol ,2010, 119（6）: 689-702.
［16］Del Tredici K, Hawkes CH, Ghebremedhin E, et al. Lewy pathology in the submandibular gland of individuals with incidental Lewy body disease and sporadic Parkinson's disease［J］. Acta Neuropathol 2010, 119(6): 703-713.
［17］Khoo TK, Yarnall AJ, Duncan GW, et al. The spectrum of non-motor symptoms in early Parkinson's disease［J］. Neurology, 2013, 80(3): 276-281.
［18］Postuma RB, Aarsland D, Barone P, et al. Identifying prodromal Parkinson's disease:pre-motor disorders in Parkinson's disease［J］. Mov Disord, 2012, 27(5): 617-626.
［19］Braak H, de Vos RA, Bohl J, et al. Gastric alpha-synuclein immunoreactive inclusions in Meissner's and Auerbach's plexuses in cases staged for Parkinson's disease-related brain pathology［J］. Neurosci Lett, 2006,396(1):67-72.
［20］Kumari R, Kumar JB, Luthra PM. Post-lesion administration of 7-NI attenuated motor and non-motor deficits in 6-OHDA induced bilaterally lesioned female rat model of Parkinson's disease［J］. Neurosci Lett, 2015, 589:191-195.
［21］Beal MF. Mitochondria take center stage in aging and neurodegeneration［J］. Ann Neurol, 2005, 58(4): 495-505.
［22］Patil SP, Jain PD, Ghumatkar PJ, et al. Neuroprotective effect of metformin in MPTP-induced Parkinson's disease in mice［J］. Neuroscience, 2014, 277:747-754.
［23］Dickson DW.Parkinson's disease and parkinsonism: neuropathology［J］.Cold Spring Harb Perspect Med,2012,2(8):pii:a009258.
［24］Masters CL, Kril JJ, Halliday GM, et al. Overview and recent advances in neuropathology. Part 2: Neurodegeneration［J］. Pathology, 2011,43(2): 93-102.
［25］Spillantini MG, Schmidt ML, Lee VM, et al. Alpha-synuclein in Lewy bodies［J］. Nature,1997,388(6645): 839-840.
［26］Goedert M, Spillantini MG, Del Tredici K, et al. 100 years of Lewy pathology［J］. Nat Rev Neurol, 2013, 99(1): 13-24.
［27］LiuY, Qiang M, Wei Y, et al. A novel molecular mechanism for nitrated α-synuclein-induced cell death［J］. J Mol Cell Biol,2011, 3(4):239-249.
［28］ Lee JK, Tran T, Tansey MG. Neuroinflammation in Parkinson's disease［J］. J Neuroimmune Pharmacol, 2009, 4(4): 419-429.
［29］Breidert T, Callebert J, Heneka MT, et al. Protective action of the peroxisome proliferator-activated receptor-gamma agonist pioglitazone in a mouse model of Parkinson's disease［J］. J Neurochem, 2002, 82（3）, 615-624.
［30］Gao HM, Hong JS. Why neurodegenerative diseases are progressive: uncontrolled inflammation drives disease progression［J］. Trends Immunol, 2008, 29(8): 357-365.

[1]	ZHANG Lei, XIAO Xingpeng, DING Huang . Silencing ZKSCAN3 gene expression aggravates lung injury induced by LPS in mice [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(2): 164-170.
[2]	FU Xiaomei, HUO Ran, DENG Sai, LIN Chaojin, FAN Jinghao, WANG Ping, LI Songpei, QIN Aiping, ZOU Minghui, YU Xiyong. Exosomes derived from LPS-stimulated bone marrow mesenchymal stem cell improve myocardial inflammation and fibrosis after myocardial infarction in mice [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2019, 24(8): 841-851.
[3]	LIU Huanmiao, CHEN Zhuohui, WU Di, HUANG Xueting, WAN Qiquan. Insulin attenuates the inhibition effect of lipopolysaccharide on Na+-K+-ATPase α1 via PI3K/AKT and PI3K/ERK pathway [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2019, 24(8): 896-902.
[4]	HAN Chenyang, ZHANG Xiaoling, YANG Yi, GUO Li, GUAN Qiaobing. α-synuclein activates NLRP3 inflammatory bodies to mediated nerve cell pyroptosis [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2019, 24(6): 637-643.
[5]	CHEN Shaozhong, LIN Meise, CHENG Limin, ZHU Lele. Effects of salidroside injection on pulmonary vascular permeability in rats with septic shock induced lung injury induced by lipopolysaccharide [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2019, 24(11): 1256-1262.
[6]	CAO Yingya, CHEN Qun, WANG Zhen, WU Jingyi, JIANG Xiaogan, JIN Xiaoju, LU Weihua. Role of macrophages in LPS-induced apoptosis of intestinal epithelial cells [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2019, 24(10): 1142-1146.
[7]	ZHENG Shuang, FU Qinlei, ZHOU Lingping, PENG Chuanpeng, XU Honglei. Study on interleukin-17A during early inflammatory response in mice with LPS-induced acute lung injury [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2018, 23(2): 148-153.
[8]	ZHONG Zhengling，ZHANG Fei，JIANG Yuhua，ZHANG Weiting，TONG Jiucui，LI Juan，CHU Jiru，XIE Haitang. Protective effects of Ferulic acid on acute liver injury induced by D-GalN/LPS in mice [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2018, 23(12): 1335-1339.
[9]	WANG Di, ZHANG Huanhuan, FANG Jie, ZHONG Yushen, YU Chenhuan. Effects of limoninon on LPS-induced acute lung injury in mice [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2018, 23(1): 8-12.
[10]	LIU Xiaolin, YU Meiling, XIE Jing, ZHANG Lina, XU Wenfang, YE Ming, LI Qianqian, CHEN Yuhua. Study on the relationship between constipation, colonic mucosal inflammation, intestinal LPS and Parkinson's disease [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2017, 22(4): 456-460.
[11]	CHEN Yan, YE Bin, MOU Wen-yuan, YU Cheng-bo, LIN Bu, YIN Xiang-peng, XU Hong-miao. Effect of anti-tumor necrosis factor antibody on TRAIL and TNF-α expression induced by lipopolysaccharide in human periodontal ligament fibroblasts [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2015, 20(5): 493-498.
[12]	MO Hong-ying, JIANG Yong-nan, LI Yi-min, LAI Le, XIAO Zheng-lun. Effect of MIF siRNA on the expression of Toll-like receptors and down stream signaling components in A549 cells [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2013, 18(4): 382-387.
[13]	CHEN Jie, LI Rui-ming, XU Jing, GUAN Bi-qiong, LUO Zi-ling. Effect of Wedelolactone on COX-2, NO and TNF-α expression in lipopolysaccharide induced RAW264.7 cells [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2012, 17(2): 171-174.
[14]	ZHU Hai-long, ZHANG Gen-bao, LI Wei, ZHANG Cui. Protective effects of ERK1/2 inhibitor PD98059 on multiple organ dysfunction in disseminated- intravascular-coagulation rat [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2012, 17(2): 159-163.
[15]	YU Meng-chen, PAN Xi-chun, LI Xiao-li, LI Jun, XIAO Kang-kang, LI Bin, ZHOU Hong. Artesunate enhance the ability of peritoneal macrophages endocytosing LPS and Escherichia coli and its mechnisms [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2012, 17(1): 40-46.